Elizabeth Ornelas
Novartis (Switzerland)(CH)Novartis (China)(CN)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Synthesis and biological activity, Protein Degradation and Inhibitors, Cancer Mechanisms and Therapy, Antenna Design and Analysis
Most-Cited Works
- → Harnessing the anti-cancer natural product nimbolide for targeted protein degradation(2019)412 cited
- → Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy(2023)141 cited
- → Novel Potent and Selective Inhibitors of p90 Ribosomal S6 Kinase Reveal the Heterogeneity of RSK Function in MAPK-Driven Cancers(2014)76 cited
- → A molecular glue degrader of the WIZ transcription factor for fetal hemoglobin induction(2024)73 cited
- → Targeting the trypanosome kinetochore with CLK1 protein kinase inhibitors(2020)70 cited
- → Rationally Designed PI3Kα Mutants to Mimic ATR and Their Use to Understand Binding Specificity of ATR Inhibitors(2017)40 cited
- → Two Distinct Mechanisms of Inhibition of LpxA Acyltransferase Essential for Lipopolysaccharide Biosynthesis(2020)39 cited
- → Identification and structure–activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors(2010)30 cited
- → 2-Amino-7-substituted benzoxazole analogs as potent RSK2 inhibitors(2014)27 cited